Gilled is an extremely strong company fundamentally with huge earnings growth. Stock was hid with uncertainty with competition or ABBY but their new Hep C drugs should still control 80-90% of market share. Also the retracement off the recent high has found solid support at the $100 level. The stock looks ready for a move higher